secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001171843-25-002817
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics Q1 revenue up 36% to $17.6M; net loss widens; raises 2025 guidance
-------------------------------------------------------------------------------

- Net sales $17.6M (+36% YoY); DME $13.8M (+14%), PBP $3.8M (+360%).
- Installed customer base 19,151 (+291%); 3,853 new patient starts (+48%).
- Gross margin 50.9% (down 482 bps); operating loss $18.6M; net loss $28.7M.
- Cash and investments $295.5M as of March 31, 2025.
- Raised full-year 2025 annual guidance (specific numeric targets not in excerpt).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184325002817/0001171843-25-002817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184325002817/f8k_050625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer